We aim to do so by continual application of novel, ground-breaking technologies, medical algorithms (AI), and distribution models. Our mission is to save lives by detecting cancer in the early and curable stages. Our initial focus is on skin.
Inefficient diagnostic tools cause high numbers of unnecessary referrals
Discriminating a case of malignant melanoma from normal moles requires training, experience and a dermatoscope. Only 8% of General Practitioners (GPs) in France possess a dermatoscope (1), with similar uptake rates across Western countries. This leads to a disproportionate number of benign biopsies.
Late diagnosis of Malignant Melanoma
Early detection is key for survival of skin cancer. When caught early, the 5-year survival rate from malignant melanoma is 98%. However, the 5-year survival rate falls to just 23% when melanoma metastasizes to distant organs (2). Treatment costs for late stage therapy are also very expensive, estimated to be as high as $495,000 per patient (3).
Long waiting time for dermatologist consultations
Guidelines give priority to potential cancer patients, and inefficient diagnostic tools mean that an excessive number of patients are referred to secondary care. This results in long waiting times for curable skin issues with a big impact on the quality of life.
DeepX Health seeks to disrupt the current diagnostic pathway of skin conditions. Our mission is to save lives by having more patients checked early, less inappropriate biopsies and fewer missed cases of malignant melanoma
DeepX Diagnostics Inc.
2101 L St NW
Washington, District of Columbia 20037
United States of America
Bergen High Technology Centre
Thormøhlens gate 55
5008 Bergen
Norway
Innovation Centre
Maidstone Road
Chatham
Kent ME5 9FD
United Kingdom
Christian Horn / CEO
christian.horn@deepxhealth.com
+47 901 63 153